Calyxo was founded in February 2016 to address the profound need for improved kidney stone treatment. Kidney stone disease is a common problem that is painful and consumes vast amounts of healthcare resources each year. Calyxo is focused on delivering innovative solutions to better meet the needs of kidney stone patients and transform the care of this condition.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/07/22 | $32,700,000 | Series C |
CRG Questa Capital | undisclosed |
| 12/12/23 | $50,000,000 | Series D |
Avidity Partners CRG Questa Capital | undisclosed |
